Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$73.90 USD
+1.58 (2.18%)
Updated May 3, 2024 04:00 PM ET
After-Market: $73.99 +0.09 (0.12%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth D Momentum D VGM
Brokerage Reports
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 141 - 160 ( 714 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
3Q20 Results; Moving Toward Year-End on Real Solid Footing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Analyst Day Highlights; Continuing to Kick It up a Notch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Nonstop Strategic Moves; Vernalis Divested but Royalty Potential Remains
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Updated Model Post Pfenex/Captisol - Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Ever-Expanding OmniAb Footprint; Continued Strategic Cash Deployment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Kyprolis Sees Next Positive Inflection; Multiple Revenue Streams a Major Factor to Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J